Disclosure: The study to which this correspondence refers was sponsored by Pozen, Inc., and supported by GlaxoSmithKline, Research Triangle Park, NC. S.D. Silberstein is on the Advisory Panel or Speaker's Bureau for Allergan, AstraZeneca, Endo Pharmaceuticals, GlaxoSmithKline, Medtronic, Merck, Ortho-McNeil, Pfizer, Pozen, and Valeant Pharmaceuticals. He receives research support from Abbott, Advanced Bionics, AGA, Advanced Neuro-Modulation Systems, Allergan, AstraZeneca, Endo Pharmaceuticals, Lilly, GlaxoSmithKline, Medtronic, Merck, OrthoMcNeil, Pfizer, Pozen, Pro-Ethic, Valeant Pharmaceuticals, and Vernalis. L.K. Mannix has served on the Advisory Board, Speaker's Bureau, or as a consultant for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Merck, OMN, and Pfizer. She also receives research grants from Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Merck, OMN, Pozen, and Alexza. J. Goldstein has served as a Consultant and/or served on Advisory Boards, Speaker Bureaus, conducted and/or received research support from Abbott Laboratories, Agouron Pharmaceuticals, Allergan Inc., Almirall, Alza Pharmaceuticals, Applied Analytical Industries, AstraZeneca, Bayer Corporation, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Bristol-Myers Products, Capnia Inc., Carnrick Laboratories, Cephalon Inc., Corcept Therapeutics, Daiichi Suntory Pharma, Eisai Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Pharmaceuticals, Fujisawa Healthcare Inc., GlaxoSmithKline, Janssen/Johnson and Johnson, RWJohnson Pharmaceutical Research Institute, McNeil Consumer and Specialty Pharmaceuticals, Merck and Company, Mylan Pharmaceuticals, NPS Pharmaceutical, Neo Therapeutic, Novartis Pharmaceuticals, Ortho McNeil Pharmaceuticals, Parke-Davis, Pfizer Inc., Pharmacia, Pharmacia and Upjohn, Pozen, Proctor&Gamble, Renovis Inc., Roche Pharmaceuticals, Saegis Pharmaceuticals Inc., Sandoz Pharmaceuticals, Sanofi-Synthelabo Inc., Schwarz Bioscience, GD Searle, Syntex, UCB Pharma Inc., Vanguard Medica, Vernalis, Winston Laboratories, and Wyeth-Ayerst. J.R. Couch has received research support from GlaxoSmithKline, Astra Zeneca, Merck, Pfizer, Ortho-McNeil, and Schwarz. He has also participated in Speakers Bureaus or Advisory Boards for GlaxoSmithKline, Astra Zeneca, Merck, Pfizer, and Ortho-McNeil. S.C. Byrd, M.H. Ames, S.A. McDonald, and S.E. Lener are current employees of GlaxoSmithKline, and M.H. Ames carried out the biostatistical analysis.

Editors' Note: After review by the Editors and further clarification by the authors, it was determined that Cynthia Toso played a role in drafting the original Silberstein et al. manuscript. Ms. Toso was included in the Acknowledgment but should have been included in the byline as a coauthor. *Neurology*[®]'s policy, effective December 15, 2006, states: "Manuscripts submitted for publication must list all authors, *including the person who drafted the original manuscript*. This includes paid or unpaid medical writers ('ghost writers')." A Correction noting the error is included in this issue.

Copyright © 2009 by AAN Enterprises, Inc.

1. Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. *Neurology* 2008;71:114–121.
2. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. *Headache* 2005;45:983–991.
3. Available at: www.drugstore.com and www.shopping.com. Accessed August 1, 2008.
4. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. *Clin Ther* 2005;27:1785–1794.
5. Fox AW, Keywood C, Sheftell FD, Spierings ELH, Winner P. Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT_{1B/1D} agonist efficacy in migraine. *Headache* 2002;42:680–688.
6. Goadsby PJ, Ferrari MD, Lipton RB. Therapeutic gain or therapeutic ratio? *Headache* 2003;43:814–815; author reply 815–816.
7. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature: XIX: applying clinical trial results B Guidelines for determining whether a drug is exerting (more than) a class effect. *JAMA* 1999;282:1371–1377.

CORRECTION

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

In the article "Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine" by S.D. Silberstein et al. (*Neurology*[®] 2008;71:114–121), the authors include Cynthia Toso, PharmD, in the Acknowledgment. Dr. Toso should have been included in the byline as an author for her role in helping to draft the original manuscript.

Disclosures: Cynthia Toso received funding for her work on this project and other writing-related projects from GlaxoSmithKline. She is a former employee of GlaxoSmithKline. Her husband is an employee of and has equity interests in GlaxoSmithKline.

Neurology[®]

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

Neurology 2009;72;1369

DOI 10.1212/01.wnl.0000344301.82495.c6

This information is current as of April 13, 2009

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/72/15/1369.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.